{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T06:34:26Z","timestamp":1717914866790},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T00:00:00Z","timestamp":1305072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Renal Care"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Secondary hyperparathyroidism is a characteristic feature of chronic kidney disease, which develops early in the course of chronic kidney disease, often in a progressive way. It occurs as the renal function continues to decline and is encountered following a series of biochemical abnormalities, which are responsible for initiation and maintenance of increased parathyroid hormone (PTH) secretion.<\/jats:p><jats:p>Several agents are used in the management of secondary hyperparathyroidism. Paricalcitol is a new generation selective vitamin D receptor activator that lowers PTH levels by exerting a less hypercalcaemic and hyperphosphataemic effect. In addition, there is emerging evidence of the benefit of paricalcitol in preventing intravascular calcification and proteinuria.<\/jats:p>","DOI":"10.1111\/j.1755-6686.2011.00230.x","type":"journal-article","created":{"date-parts":[[2011,5,11]],"date-time":"2011-05-11T13:16:42Z","timestamp":1305119802000},"page":"75-79","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PARICALCITOL IN SECONDARY HYPERPARATHYROIDISM AND THE SURVIVAL BENEFIT IN PATIENTS WITH CHRONIC KIDNEY DISEASE"],"prefix":"10.1111","volume":"37","author":[{"given":"Fouad","family":"Al\u2010Baaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriece","family":"Al\u2010Rifai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,11]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Abbott Laboratories Ltd. (2005a).Summary basis of decision (SBD) Paricalcitol Health Canada Abbott Laboratories Ltd Date issued 18\/11\/2005."},{"key":"e_1_2_11_3_1","unstructured":"Abbott Laboratories. (2005b).Zemplar (Paricalcitol) injection prescribing information. Canada March 2005."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00755.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.113159"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200201050-00004"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2002.122819"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070305"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(00)00150-1"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.6.947"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.22"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh123"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88299-5"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000178251"},{"key":"e_1_2_11_15_1","first-page":"315","article-title":"A long\u2010term, multicenter study of the efficacy and safety of paricalcitol in end\u2010stage renal disease","volume":"56","author":"Lindberg J.","year":"2001","journal-title":"Clinical Nephrology"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28114"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000266204"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19\u2010Nor\u20101\u2010alpha\u201025\u2010dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin K.J.","year":"1998","journal-title":"Journal of American Society of Nephrology"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002406"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006091028"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn375"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.532"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000109398"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07305.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00878.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022536"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004070573"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn592"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61032-X"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803751105"}],"container-title":["Journal of Renal Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-6686.2011.00230.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-6686.2011.00230.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:04:42Z","timestamp":1697259882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-6686.2011.00230.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,11]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1755-6686.2011.00230.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-6686.2011.00230.x","archive":["Portico"],"relation":{},"ISSN":["1755-6678","1755-6686"],"issn-type":[{"value":"1755-6678","type":"print"},{"value":"1755-6686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,11]]},"assertion":[{"value":"2011-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}